Angiogenesis and hypoxic factors in colorectal cancer

Pathology Research and Practice

Volumn 204, Issue 7, 2008, Pages 501-510

  Rasheed, Shahnawaz ^a   McDonald, Peter J ^a   Northover, John M ^a   Guenther, Thomas ^a  

^a ST MARK S HOSPITAL   (United Kingdom)

Author keywords

Angiogenesis; Cancer; Colon; Hypoxia; Rectum

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CAPECITABINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; VASCULOTROPIN; VASCULOTROPIN INHIBITOR; VASCULOTROPIN RECEPTOR; VATALANIB;

ANGIOGENESIS; ARTICLE; CANCER CELL; CANCER GROWTH; CANCER INHIBITION; CANCER SURVIVAL; CELL HYPOXIA; CELL PROLIFERATION; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COLON CARCINOGENESIS; COLORECTAL CANCER; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; DRUG SAFETY; ENDOTHELIUM CELL; EPISTAXIS; EXTRACELLULAR MATRIX; HEART MUSCLE ISCHEMIA; HUMAN; HYPERTENSION; HYPOXIA; IMMUNOHISTOCHEMISTRY; METASTASIS POTENTIAL; MICROVASCULARIZATION; MONOTHERAPY; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; OVERALL SURVIVAL; OXYGEN CONSUMPTION; PRECANCER; PROTEIN DETERMINATION; PROTEIN FUNCTION; PROTEINURIA; THROMBOEMBOLISM; THROMBOSIS; TRANSIENT ISCHEMIC ATTACK; TUMOR VASCULARIZATION; UNSPECIFIED SIDE EFFECT;

ANGIOGENESIS INDUCING AGENTS; ANIMALS; CELL HYPOXIA; COLORECTAL NEOPLASMS; DISEASE MODELS, ANIMAL; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; MICE; NEOVASCULARIZATION, PATHOLOGIC; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 46749115939     PISSN: 03440338     EISSN: 16180631     Source Type: Journal    
DOI: 10.1016/j.prp.2008.03.005     Document Type: Article

References (126)

1. Asahara T., Kalka C., and Isner J.M. Stem cell therapy and gene transfer for regeneration. Gene Ther. 7 (2000) 451-457
2. Barbera-Guillem E., Nyhus J.K., Wolford C.C., Friece C.R., and Sampsel J.W. Vascular endothelial growth factor secretion by tumor-infiltrating macrophages essentially supports tumor angiogenesis, and IgG immune complexes potentiate the process. Cancer Res. 62 (2002) 7042-7049
3. Beasley N.J., Wykoff C.C., Watson P.H., Leek R., Turley H., Gatter K., Pastorek J., Cox G.J., Ratcliffe P., and Harris A.L. Carbonic anhydrase IX, an endogenous hypoxia marker, expression in head and neck squamous cell carcinoma and its relationship to hypoxia, necrosis, and microvessel density. Cancer Res. 61 (2001) 5262-5267
4. Benson III A.B. Adjuvant chemotherapy of stage III colon cancer. Semin. Oncol. 32 (2005) S74-S77
5. Boedefeld II W.M., Bland K.I., and Heslin M.J. Recent insights into angiogenesis, apoptosis, invasion, and metastasis in colorectal carcinoma. Ann. Surg. Oncol. 10 (2003) 839-851
6. Borgstrom P., Gold D.P., Hillan K.J., and Ferrara N. Importance of VEGF for breast cancer angiogenesis in vivo: implications from intravital microscopy of combination treatments with an anti-VEGF neutralizing monoclonal antibody and doxorubicin. Anticancer Res. 19 (1999) 4203-4214
7. Bossi P., Viale G., Lee A.K., Alfano R., Coggi G., and Bosari S. Angiogenesis in colorectal tumors: microvessel quantitation in adenomas and carcinomas with clinicopathological correlations. Cancer Res. 55 (1995) 5049-5053
8. Bouck N., Stellmach V., and Hsu S.C. How tumors become angiogenic. Adv. Cancer Res. 69 (1996) 135-174
9. Brewer C.A., Liao S.Y., Wilczynski S.P., Pastorekova S., Pastorek J., Zavada J., Kurosaki T., Manetta A., Berman M.L., DiSaia P.J., and Stanbridge E.J. A study of biomarkers in cervical carcinoma and clinical correlation of the novel biomarker MN. Gynecol. Oncol. 63 (1996) 337-344
10. Kmietowicz Z. British cancer death rates fell by 12% between 1972 and 2002. Br. Med J. 328 (2004) 303
11. Cancer incidence, mortality and prevalence in the European Union, EUCAN 1998 estimates, International Agency for Research on Cancer, Brussels, 1998.
12. Carmeliet P., and Jain R.K. Angiogenesis in cancer and other diseases. Nature 407 (2000) 249-257
13. Chia S.K., Wykoff C.C., Watson P.H., Han C., Leek R.D., Pastorek J., Gatter K.C., Ratcliffe P., and Harris A.L. Prognostic significance of a novel hypoxia-regulated marker, carbonic anhydrase IX, in invasive breast carcinoma. J. Clin. Oncol. 19 (2001) 3660-3668
14. Choi H.J., Hyun M.S., Jung G.J., Kim S.S., and Hong S.H. Tumor angiogenesis as a prognostic predictor in colorectal carcinoma with special reference to mode of metastasis and recurrence. Oncology 55 (1998) 575-581
15. Clark E., Clark E., and Williams R. Microscopic observations on the growth of blood capillaries in the living mammal. Am. J. Anat. 64 (1939) 251-301
16. Cliff W. Observations on healing tissues: a combined light and elctron microscope investigation. Philos. Trans. R. Soc. Lond. 246 (1963) 305-325
17. Cockman M.E., Masson N., Mole D.R., Jaakkola P., Chang G.W., Clifford S.C., Maher E.R., Pugh C.W., Ratcliffe P.J., and Maxwell P.H. Hypoxia inducible factor-alpha binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein. J. Biol. Chem. 275 (2000) 25733-25741
18. Colorectal Cancer Factsheet. Cancer Research UK, 2005.
19. Conway E.M., Collen D., and Carmeliet P. Molecular mechanisms of blood vessel growth. Cardiovasc. Res. 49 (2001) 507-521
20. Couvelard A., O'Toole D., Turley H., Leek R., Sauvanet A., Degott C., Ruszniewski P., Belghiti J., Harris A.L., Gatter K., and Pezzella F. Microvascular density and hypoxia-inducible factor pathway in pancreatic endocrine tumours: negative correlation of microvascular density and VEGF expression with tumour progression. Br. J. Cancer 92 (2005) 94-101
21. Darland D.C., and D'Amore P.A. Blood vessel maturation: vascular development comes of age. J. Clin. Invest. 103 (1999) 157-158
22. de Gramont A., Figer A., Seymour M., Homerin M., Hmissi A., Cassidy J., Boni C., Cortes-Funes H., Cervantes A., Freyer G., Papamichael D., Le Bail N., Louvet C., Hendler D., de Braud F., Wilson C., Morvan F., and Bonetti A. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J. Clin. Oncol. 18 (2000) 2938-2947
23. Drevs J., Muller-Driver R., Wittig C., Fuxius S., Esser N., Hugenschmidt H., Konerding M.A., Allegrini P.R., Wood J., Hennig J., Unger C., and Marme D. PTK787/ZK 222584, a specific vascular endothelial growth factor-receptor tyrosine kinase inhibitor, affects the anatomy of the tumor vascular bed and the functional vascular properties as detected by dynamic enhanced magnetic resonance imaging. Cancer Res. 62 (2002) 4015-4022
24. Dukes C. The classification of cancer of the rectum. J. Pathol. Bacteriol. 35 (1932) 323-332
25. Eliceiri B.P., Paul R., Schwartzberg P.L., Hood J.D., Leng J., and Cheresh D.A. Selective requirement for Src kinases during VEGF-induced angiogenesis and vascular permeability. Mol. Cell 4 (1999) 915-924
26. Engel C.J., Bennett S.T., Chambers A.F., Doig G.S., Kerkvliet N., and O'Malley F.P. Tumor angiogenesis predicts recurrence in invasive colorectal cancer when controlled for Dukes staging. Am. J. Surg. Pathol. 20 (1996) 1260-1265
27. Ferrara N. Molecular and biological properties of vascular endothelial growth factor. J. Mol. Med. 77 (1999) 527-543
28. Ferrara N., and Henzel W.J. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem. Biophys. Res. Commun. 161 (1989) 851-858
29. Ferrara N., Hillan K.J., Gerber H.P., and Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat. Rev. Drug Discov. 3 (2004) 391-400
30. J. Folkman, Carcinoma of the Colon and Antecedent Epithelium, 1970, pp. 113-127.
31. Folkman J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 285 (1971) 1182-1186
32. Folkman J., and Klagsbrun M. Angiogenic factors. Science 235 (1987) 442-447
33. Folkman J., Long Jr. D.M., and Becker F.F. Growth and metastasis of tumor in organ culture. Cancer 16 (1963) 453-467
34. Folkman J., Merler E., Abernathy C., and Williams G. Isolation of a tumor factor responsible or angiogenesis. J. Exp. Med. 133 (1971) 275-288
35. Fontanini G., Lucchi M., Vignati S., Mussi A., Ciardiello F., De Laurentiis M., De Placido S., Basolo F., Angeletti C.A., and Bevilacqua G. Angiogenesis as a prognostic indicator of survival in non-small-cell lung carcinoma: a prospective study. J. Natl. Cancer Inst. 89 (1997) 881-886
36. Gasparini G., Weidner N., Maluta S., Pozza F., Boracchi P., Mezzetti M., Testolin A., and Bevilacqua P. Intratumoral microvessel density and p53 protein: correlation with metastasis in head-and-neck squamous-cell carcinoma. Int. J. Cancer 55 (1993) 739-744
37. Gerber H.P., Dixit V., and Ferrara N. Vascular endothelial growth factor induces expression of the antiapoptotic proteins Bcl-2 and A1 in vascular endothelial cells. J. Biol. Chem. 273 (1998) 13313-13316
38. B. Giantonio, P. Catalano, N. Meropol, E. Mitchell, M. Schwartz, S. Alberts, P. O'Dwyer, A. Benson, High-dose bevacizumab in combination with FOLFOX4 improves survival in patients with previously treated advanced colorectal cancer: results from the Eastern Cooperative Oncology Group (ECOG) study E3200, in: American Society of Clinical Oncology, Orlando, FL, USA, 2005.
39. Giatromanolaki A., Koukourakis M.I., Sivridis E., Pastorek J., Wykoff C.C., Gatter K.C., and Harris A.L. Expression of hypoxia-inducible carbonic anhydrase-9 relates to angiogenic pathways and independently to poor outcome in non-small cell lung cancer. Cancer Res. 61 (2001) 7992-7998
40. Goh V., Padhani A.R., and Rasheed S. Functional imaging of colorectal cancer angiogenesis. Lancet Oncol. 8 (2007) 245-255
41. Goldberg R.M., Sargent D.J., Morton R.F., Fuchs C.S., Ramanathan R.K., Williamson S.K., Findlay B.P., Pitot H.C., and Alberts S.R. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J. Clin. Oncol. 22 (2004) 23-30
42. Goldman E. The growth of malignant disease in man and the lower animals with special reference to the vascular system. Lancet 2 (1907) 1236-1240
43. Graziano F., and Cascinu S. Prognostic molecular markers for planning adjuvant chemotherapy trials in Dukes' B colorectal cancer patients: how much evidence is enough?. Ann. Oncol. 14 (2003) 1026-1038
44. Grothey A., and Sargent D. Overall survival of patients with advanced colorectal cancer correlates with availability of fluorouracil, irinotecan, and oxaliplatin regardless of whether doublet or single-agent therapy is used first line. J. Clin. Oncol. 23 (2005) 9441-9442
45. Hanahan D., and Weinberg R.A. The hallmarks of cancer. Cell 100 (2000) 57-70
46. Hata J. Morphological studies on tumour angiogenesis. Microvasc. Res. 23 (1981) 131-147
47. J. Hecht, T. Trarbach, E. Jaeger, J. Hainsworth, R. Wolff, K. Lloyd, G. Bodoky, M. Borner, D. Laurent, C. Jaques, A randomized, double-blind, placebo-controlled, phase III study in patients (Pts) with metastatic adenocarcinoma of the colon or rectum receiving first-line chemotherapy with oxaliplatin/5-fluorouracil/leucovorin and PTK787/ZK 222584 or placebo (CONFIRM-1), in: American Society of Clinical Oncology, Orlando, FL, USA, 2005.
48. Hicklin D.J., and Ellis L.M. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J. Clin. Oncol. 23 (2005) 1011-1027
49. Hlatky L., Hahnfeldt P., and Folkman J. Clinical application of antiangiogenic therapy: microvessel density, what it does and doesn't tell us. J. Natl. Cancer Inst. 94 (2002) 883-893
50. Hobday T., and Erlichman C. Colorectal Cancer in Prognostic Factors in Cancer. second ed. (2001), Wiley-Liss
51. Hobson B., and Denekamp J. Endothelial proliferation in tumours and normal tissues: continuous labelling studies. Br. J. Cancer 49 (1984) 405-413
52. Holash J., Maisonpierre P.C., Compton D., Boland P., Alexander C.R., Zagzag D., Yancopoulos G.D., and Wiegand S.J. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 284 (1999) 1994-1998
53. Holmgren L., O'Reilly M.S., and Folkman J. Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat. Med. 1 (1995) 149-153
54. 2-dependent degradation domain via the ubiquitin-proteasome pathway. Proc. Natl. Acad. Sci. USA 95 (1998) 7987-7992
55. Hurwitz H., Fehrenbacher L., Novotny W., Cartwright T., Hainsworth J., Heim W., Berlin J., Baron A., Griffing S., Holmgren E., Ferrara N., Fyfe G., Rogers B., Ross R., and Kabbinavar F. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 350 (2004) 2335-2342
56. Hynninen P., Vaskivuo L., Saarnio J., Haapasalo H., Kivela J., Pastorekova S., Pastorek J., Waheed A., Sly W.S., Puistola U., and Parkkila S. Expression of transmembrane carbonic anhydrases IX and XII in ovarian tumours. Histopathology 49 (2006) 594-602
57. Illig L. Die terminale Strombahn. Capillarbett und Mikrozirkulation vol. 10 (1961), Springer, Berlin, Göttingen, Heidelberg
58. International Union Against Cancer (UICC): Prognostic Factors in Cancer, Springer, Berlin, Heidelberg, New York, 1995.
59. Ivanov S., Liao S., Ivanova A., Danilkovitch-Miagkova A., Tarasova N., Weirich G., Merril M., Proescholdt M., Oldfield E., Lee J., Zavada J., Waheed A., Sly W., Lerman M., and Stanbridge E. Expression of hypoxia-inducible cell-surface transmembrane carbonic anhydrases in human cancer. Am. J. Pathol. 158 (2001) 905-919
60. Jaeger T.M., Weidner N., Chew K., Moore D.H., Kerschmann R.L., Waldman F.M., and Carroll P.R. Tumor angiogenesis correlates with lymph node metastases in invasive bladder cancer. J. Urol. 154 (1995) 69-71
61. Jain R.K. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307 (2005) 58-62
62. Jubb A.M., Hurwitz H.I., Bai W., Holmgren E.B., Tobin P., Guerrero A.S., Kabbinavar F., Holden S.N., Novotny W.F., Frantz G.D., Hillan K.J., and Koeppen H. Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer. J. Clin. Oncol. 24 (2006) 217-227
63. Kabbinavar F., Hurwitz H.I., Fehrenbacher L., Meropol N.J., Novotny W.F., Lieberman G., Griffing S., and Bergsland E. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J. Clin. Oncol. 21 (2003) 60-65
64. Keck P.J., Hauser S.D., Krivi G., Sanzo K., Warren T., Feder J., and Connolly D.T. Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science 246 (1989) 1309-1312
65. Kim K.J., Li B., Winer J., Armanini M., Gillett N., Phillips H.S., and Ferrara N. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362 (1993) 841-844
66. Kimura H., Weisz A., Kurashima Y., Hashimoto K., Ogura T., D'Acquisto F., Addeo R., Makuuchi M., and Esumi H. Hypoxia response element of the human vascular endothelial growth factor gene mediates transcriptional regulation by nitric oxide: control of hypoxia-inducible factor-1 activity by nitric oxide. Blood 95 (2000) 189-197
67. Klagsbrun M., Knighton D., and Folkman J. Tumor angiogenesis activity in cells grown in tissue culture. Cancer Res. 36 (1976) 110-114
68. Knighton D.R., Silver I.A., and Hunt T.K. Regulation of wound-healing angiogenesis-effect of oxygen gradients and inspired oxygen concentration. Surgery 90 (1981) 262-270
69. Knighton D.R., Hunt T.K., Scheuenstuhl H., Halliday B.J., Werb Z., and Banda M.J. Oxygen tension regulates the expression of angiogenesis factor by macrophages. Science 221 (1983) 1283-1285
70. Krishnamachary B., Berg-Dixon S., Kelly B., Agani F., Feldser D., Ferreira G., Iyer N., LaRusch J., Pak B., Taghavi P., and Semenza G.L. Regulation of colon carcinoma cell invasion by hypoxia-inducible factor 1. Cancer Res. 63 (2003) 1138-1143
71. Kumar H., Heer K., Lee P.W., Duthie G.S., MacDonald A.W., Greenman J., Kerin M.J., and Monson J.R. Preoperative serum vascular endothelial growth factor can predict stage in colorectal cancer. Clin. Cancer Res. 4 (1998) 1279-1285
72. Kuszyk B.S., Corl F.M., Franano F.N., Bluemke D.A., Hofmann L.V., Fortman B.J., and Fishman E.K. Tumor transport physiology: implications for imaging and imaging-guided therapy. AJR Am. J. Roentgenol. 177 (2001) 747-753
73. Lee J.C., Chow N.H., Wang S.T., and Huang S.M. Prognostic value of vascular endothelial growth factor expression in colorectal cancer patients. Eur. J. Cancer 36 (2000) 748-753
74. Leung D.W., Cachianes G., Kuang W.J., Goeddel D.V., and Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 246 (1989) 1306-1309
75. Liao S.Y., Aurelio O.N., Jan K., Zavada J., and Stanbridge E.J. Identification of the MN/CA9 protein as a reliable diagnostic biomarker of clear cell carcinoma of the kidney. Cancer Res. 57 (1997) 2827-2831
76. Loncaster J.A., Harris A.L., Davidson S.E., Logue J.P., Hunter R.D., Wycoff C.C., Pastorek J., Ratcliffe P.J., Stratford I.J., and West C.M. Carbonic anhydrase (CA IX) expression, a potential new intrinsic marker of hypoxia: correlations with tumor oxygen measurements and prognosis in locally advanced carcinoma of the cervix. Cancer Res. 61 (2001) 6394-6399
77. Maglione D., Guerriero V., Viglietto G., Delli-Bovi P., and Persico M.G. Isolation of a human placenta cDNA coding for a protein related to the vascular permeability factor. Proc. Natl. Acad. Sci. USA 88 (1991) 9267-9271
78. Maxwell P.H., Wiesener M.S., Chang G.W., Clifford S.C., Vaux E.C., Cockman M.E., Wykoff C.C., Pugh C.W., Maher E.R., and Ratcliffe P.J. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399 (1999) 271-275
79. Maxwell P.H., Pugh C.W., and Ratcliffe P.J. Activation of the HIF pathway in cancer. Curr. Opin. Genet. Dev. 11 (2001) 293-299
80. McLeod H.L., and Murray G.I. Tumour markers of prognosis in colorectal cancer. Br. J. Cancer 79 (1999) 191-203
81. Meyer M., Clauss M., Lepple-Wienhues A., Waltenberger J., Augustin H.G., Ziche M., Lanz C., Buttner M., Rziha H.J., and Dehio C. A novel vascular endothelial growth factor encoded by Orf virus, VEGF-E, mediates angiogenesis via signalling through VEGFR-2 (KDR) but not VEGFR-1 (Flt-1) receptor tyrosine kinases. EMBO J. 18 (1999) 363-374
82. Nelson A.R., Fingleton B., Rothenberg M.L., and Matrisian L.M. Matrix metalloproteinases: biologic activity and clinical implications. J. Clin. Oncol. 18 (2000) 1135-1149
83. Neufeld G., Cohen T., Gengrinovitch S., and Poltorak Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J. 13 (1999) 9-22
84. Obrand D.I., and Gordon P.H. Incidence and patterns of recurrence following curative resection for colorectal carcinoma. Dis. Colon Rectum 40 (1997) 15-24
85. Offersen B.V., Borre M., and Overgaard J. Quantification of angiogenesis as a prognostic marker in human carcinomas: a critical evaluation of histopathological methods for estimation of vascular density. Eur. J. Cancer 39 (2003) 881-890
86. Ogawa S., Oku A., Sawano A., Yamaguchi S., Yazaki Y., and Shibuya M. A novel type of vascular endothelial growth factor, VEGF-E (NZ-7 VEGF), preferentially utilizes KDR/Flk-1 receptor and carries a potent mitotic activity without heparin-binding domain. J. Biol. Chem. 273 (1998) 31273-31282
87. Olivarez D., Ulbright T., DeRiese W., Foster R., Reister T., Einhorn L., and Sledge G. Neovascularization in clinical stage A testicular germ cell tumor: prediction of metastatic disease. Cancer Res. 54 (1994) 2800-2802
88. O'Dwyer P.J. The present and future of angiogenesis-directed treatments of colorectal cancer. Oncologist 11 (2006) 992-998
89. Petrelli N., Douglass Jr. H.O., Herrera L., Russell D., Stablein D.M., Bruckner H.W., Mayer R.J., Schinella R., Green M.D., Muggia F.M., et al. The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: a prospective randomized phase III trial. Gastrointestinal Tumor Study Group. J. Clin. Oncol. 7 (1989) 1419-1426
90. Phillips P., Steward J.K., and Kumar S. Tumour angiogenesis factor (TAF) in human and animal tumours. Int. J. Cancer 17 (1976) 549-558
91. Polverini P.J., and Leibovich S.J. Induction of neovascularization in vivo and endothelial proliferation in vitro by tumor-associated macrophages. Lab. Invest. 51 (1984) 635-642
92. Prat A., Casado E., and Cortes J. New approaches in angiogenic targeting for colorectal cancer. World J. Gastroenterol. 13 (2007) 5857-5866
93. Pugh C.W., and Ratcliffe P.J. Regulation of angiogenesis by hypoxia: role of the HIF system. Nat. Med. 9 (2003) 677-684
94. Rafii S. Circulating endothelial precursors: mystery, reality, and promise. J. Clin. Invest. 105 (2000) 17-19
95. S. Rasheed, S. Harris, P. Tekkis, H. Turley, A. Silver, P.J. McDonald, I. Talbot, R. Glynne-Jones, J. Northover, T. Guenther, Hypoxia inducible factor 1α (HIF-1α), hypoxia inducible factor 2α (HIF-2α), angiogenesis and prognosis in rectal cancer, in: American Society of Colorectal Surgeons, Seattle, USA, 2006.
96. S. Rasheed, S. Harris, P. Tekkis, H. Turley, A. Silver, P.J. McDonald, I. Talbot, R. Glynne-Jones, J. Northover, T. Guenther, Microvessel density and carbonic anhydrase-9 expression, angiogenesis and prognosis in rectal cancer, in: American Society of Colorectal Suregons, Seattle, USA, 2006.
97. Ratner M. Genentech discloses safety concerns over Avastin. Nat. Biotechnol. 22 (2004) 1198
98. Rhodin J.A. Ultrastructure of mammalian venous capillaries, venules, and small collecting veins. J. Ultrastruct. Res. 25 (1968) 452-500
99. Rijhsinghani K., Greenblatt M., and Shubik P. Vascular abnormalities induced by benzo[a]pyrene: an in vivo study in the hamster cheek pouch. J. Natl. Cancer Inst. 41 (1968) 205-216
100. Robertson N., Potter C., and Harris A.L. Role of carbonic anhydrase IX in human tumor cell growth, survival, and invasion. Cancer Res. 64 (2004) 6160-6165
101. Saarnio J., Parkkila S., Parkkila A.K., Haukipuro K., Pastorekova S., Pastorek J., Kairaluoma M.I., and Karttunen T.J. Immunohistochemical study of colorectal tumors for expression of a novel transmembrane carbonic anhydrase, MN/CA IX, with potential value as a marker of cell proliferation. Am. J. Pathol. 153 (1998) 279-285
102. Saclarides T.J., Speziale N.J., Drab E., Szeluga D.J., and Rubin D.B. Tumor angiogenesis and rectal carcinoma. Dis. Colon Rectum 37 (1994) 921-926
103. Salceda S., and Caro J. Hypoxia-inducible factor 1alpha (HIF-1alpha) protein is rapidly degraded by the ubiquitin-proteasome system under normoxic conditions. Its stabilization by hypoxia depends on redox-induced changes. J. Biol. Chem. 272 (1997) 22642-22647
104. Schottenfield D. Epidemiology of Colorectal Cancer (1995), McGraw-Hill Inc. pp. 11-23
105. Semenza G.L. HIF-1 and tumor progression: pathophysiology and therapeutics. Trends Mol. Med. 8 (2002) S62-S67
106. Senger D.R., Galli S.J., Dvorak A.M., Perruzzi C.A., Harvey V.S., and Dvorak H.F. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 219 (1983) 983-985
107. Shibuya M., Ito N., and Claesson-Welsh L. Structure and function of vascular endothelial growth factor receptor-1 and -2. Curr. Top. Microbiol. Immunol. 237 (1999) 59-83
108. Sims D.E. The pericyte - a review. Tissue Cell 18 (1986) 153-174
109. Takahashi Y., Kitadai Y., Bucana C.D., Cleary K.R., and Ellis L.M. Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res. 55 (1995) 3964-3968
110. Takahashi Y., Tucker S.L., Kitadai Y., Koura A.N., Bucana C.D., Cleary K.R., and Ellis L.M. Vessel counts and expression of vascular endothelial growth factor as prognostic factors in node-negative colon cancer. Arch. Surg. 132 (1997) 541-546
111. Tanigawa N., Amaya H., Matsumura M., Lu C., Kitaoka A., Matsuyama K., and Muraoka R. Tumor angiogenesis and mode of metastasis in patients with colorectal cancer. Cancer Res. 57 (1997) 1043-1046
112. Teicher B.A., Liu S.D., Liu J.T., Holden S.A., and Herman T.S. A carbonic anhydrase inhibitor as a potential modulator of cancer therapies. Anticancer Res. 13 (1993) 1549-1556
113. Thirion P., Michiels S., Pignon J.P., Buyse M., Braud A.C., Carlson R.W., O'Connell M., Sargent P., and Piedbois P. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: an updated meta-analysis. J. Clin. Oncol. 22 (2004) 3766-3775
114. Tomisaki S., Ohno S., Ichiyoshi Y., Kuwano H., Maehara Y., and Sugimachi K. Microvessel quantification and its possible relation with liver metastasis in colorectal cancer. Cancer 77 (1996) 1722-1728
115. Uemura H., Nakagawa Y., Yoshida K., Saga S., Yoshikawa K., Hirao Y., and Oosterwijk E. MN/CA IX/G250 as a potential target for immunotherapy of renal cell carcinomas. Br. J. Cancer 81 (1999) 741-746
116. UICC TNM Classification of Malignant Tumours, sixth ed., Wiley-Liss, 2002, pp. 1-239.
117. Vermeulen P.B., Gasparini G., Fox S.B., Colpaert C., Marson L.P., Gion M., Belien J.A., de Waal R.M., Van Marck E., Magnani E., Weidner N., Harris A.L., and Dirix L.Y. Second international consensus on the methodology and criteria of evaluation of angiogenesis quantification in solid human tumours. Eur. J. Cancer 38 (2002) 1564-1579
118. Vesalainen S., Lipponen P., Talja M., Alhava E., and Syrjanen K. Tumor vascularity and basement membrane structure as prognostic factors in T1-2MO prostatic adenocarcinoma. Anticancer Res. 14 (1994) 709-714
119. Vullo D., Franchi M., Gallori E., Pastorek J., Scozzafava A., Pastorekova S., and Supuran C.T. Carbonic anhydrase inhibitors: inhibition of the tumor-associated isozyme IX with aromatic and heterocyclic sulfonamides. Bioorg. Med. Chem. Lett. 13 (2003) 1005-1009
120. Warren R.S., Yuan H., Matli M.R., Gillett N.A., and Ferrara N. Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis. J. Clin. Invest. 95 (1995) 1789-1797
121. Weidner N., Folkman J., Pozza F., Bevilacqua P., Allred E.N., Moore D.H., Meli S., and Gasparini G. Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. J. Natl. Cancer Inst. 84 (1992) 1875-1887
122. Willett C.G., Boucher Y., di Tomaso E., Duda D.G., Munn L.L., Tong R.T., Chung D.C., Sahani D.V., Kalva S.P., Kozin S.V., Mino M., Cohen K.S., Scadden D.T., Hartford A.C., Fischman A.J., Clark J.W., Ryan D.P., Zhu A.X., Blaszkowsky L.S., Chen H.X., Shellito P.C., Lauwers G.Y., and Jain R.K. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat. Med. 10 (2004) 145-147
123. Wood J.M., Bold G., Buchdunger E., Cozens R., Ferrari S., Frei J., Hofmann F., Mestan J., Mett H., O'Reilly T., Persohn E., Rosel J., Schnell C., Stover D., Theuer A., Towbin H., Wenger F., Woods-Cook K., Menrad A., Siemeister G., Schirner M., Thierauch K.H., Schneider M.R., Drevs J., Martiny-Baron G., and Totzke F. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res. 60 (2000) 2178-2189
124. Yarbro J.W., Page D.L., Fielding L.P., Partridge E.E., and Murphy G.P. American Joint Committee on Cancer prognostic factors consensus conference. Cancer 86 (1999) 2436-2446
125. Yoshimura H., Dhar D.K., Kohno H., Kubota H., Fujii T., Ueda S., Kinugasa S., Tachibana M., and Nagasue N. Prognostic impact of hypoxia-inducible factors 1alpha and 2alpha in colorectal cancer patients: correlation with tumor angiogenesis and cyclooxygenase-2 expression. Clin. Cancer Res. 10 (2004) 8554-8560
126. Zhong H., De Marzo A.M., Laughner E., Lim M., Hilton D.A., Zagzag D., Buechler P., Isaacs W.B., Semenza G.L., and Simons J.W. Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res. 59 (1999) 5830-5835